Literature DB >> 9052714

Exploring the etiology of Alzheimer disease using molecular genetics.

C L Lendon1, F Ashall, A M Goate.   

Abstract

Alzheimer disease (AD), the most common cause of dementia in the elderly, exists in both familial and sporadic forms. Genetic studies have led to the identification of 3 genes, beta-amyloid precursor protein (APP), presenilin-1 (PS1), and presenilin-2 (PS2), which, when mutated, can cause familial forms of AD. Mutations in each of these genes result in elevated levels of A beta42/43, a proteolytic processing fragment of APP that is deposited in brains of AD patients. Transgenic mice carrying AD-causing mutations in APP develop spontaneous age-related beta-amyloid (A beta) deposition and memory impairment. Genetic linkage and association studies have also shown that the epsilon4 allele of the apolipoprotein E (APOE) gene increases risk for AD in a dose-dependent manner in both familial and sporadic forms of AD and may account for as much as 50% of the attributable risk. APOE genotyping may be useful both as an adjunct to diagnosis and in identifying patient groups for therapeutic intervention. While the biological basis for the association of APOE epsilon4 with AD is not known, age of onset and A beta deposition are positively correlated with epsilon4 allele dosage in some cases, suggesting that this risk may also be mediated directly or indirectly through A beta. Because 50% of AD cases have no APOE epsilon4 alleles and families showing mendelian inheritance of AD exist in whom there are no mutations in any of the APP, PS1, or PS2 genes, it is likely that there are additional AD risk factors, both genetic and environmental, still to be identified.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9052714

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  33 in total

1.  Sandwich ELISA for the measurement of Apo-E4 levels in serum and the estimation of the allelic status of Apo-E4 isoforms.

Authors:  Y Uchida; S Ito; N Nukina
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Allele predicted accelerated rate of cognitive decline in Alzheimer's disease.

Authors:  D Burke
Journal:  West J Med       Date:  1999-07

3.  Update on Alzheimer's disease: recent findings and treatments.

Authors:  R O'Hara; M S Mumenthaler; J A Yesavage
Journal:  West J Med       Date:  2000-02

4.  Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein.

Authors:  F Zhang; C Eckman; S Younkin; K K Hsiao; C Iadecola
Journal:  J Neurosci       Date:  1997-10-15       Impact factor: 6.167

Review 5.  Memory, thinking, and aging. What we know about what we know.

Authors:  L Teri; S M McCurry; R G Logsdon
Journal:  West J Med       Date:  1997-10

Review 6.  Advances and challenges in the prevention and treatment of Alzheimer's disease.

Authors:  R Diaz Brinton; R S Yamazaki
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

7.  Failure to detect Chlamydia pneumoniae in the late-onset Alzheimer's brain.

Authors:  R H Ring; J M Lyons
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

Review 8.  What can rodent models tell us about cognitive decline in Alzheimer's disease?

Authors:  Sabrina Davis; Serge Laroche
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

Review 9.  Progress toward identification of protease activity involved in proteolysis of apolipoprotein e in human brain.

Authors:  Marcos A Marques; Phillip A Owens; Keith A Crutcher
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

10.  Genetic Modifiers of Age at Onset in Carriers of the G206A Mutation in PSEN1 With Familial Alzheimer Disease Among Caribbean Hispanics.

Authors:  Joseph H Lee; Rong Cheng; Badri Vardarajan; Rafael Lantigua; Dolly Reyes-Dumeyer; Ward Ortmann; Robert R Graham; Tushar Bhangale; Timothy W Behrens; Martin Medrano; Ivonne Z Jiménez-Velázquez; Richard Mayeux
Journal:  JAMA Neurol       Date:  2015-09       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.